A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

NCT02125344 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

961

Enrollment

OTHER

Sponsor class

Conditions

Tubular Breast Cancer Stage II
Tubular Breast Cancer Stage III
Mucinous Breast Cancer Stage II
Breast Cancer Female NOS
Invasive Ductal Breast Cancer
HER2 Positive Breast Cancer
Inflammatory Breast Cancer

Interventions

DRUG: non-pegylated liposomal doxorubicin
DRUG: Carboplatin
DRUG: Paclitaxel
DRUG: Epirubicin
DRUG: Cyclophosphamide
DRUG: Pertuzumab
DRUG: Trastuzumab
DRUG: Ferric carboxymaltose

Sponsor

GBG Forschungs GmbH

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]